Verastem Oncology Reports New Progress on VS-7375 (GFH375) in Advanced Tumors Including Pancreatic Cancer

Verastem Oncology announced updated progress on VS-7375 (GFH375), a KRAS-targeted inhibitor, across multiple advanced solid tumors including pancreatic ductal adenocarcinoma. The announcement positions the candidate alongside broader pan-RAS inhibitors that have altered treatment of KRAS-mutant solid tumors, while targeting specific KRAS mutations. No efficacy figures were included in the announcement.